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Abstract
Objective—We recently demonstrated that low-density lipoprotein receptor related protein 1 
(LRP1) is required for cardiovascular development in zebrafish. However, what role LRP1 plays 
in angiogenesis remains to be determined. To better understand the role of LRP1 in endothelial 
cell function, we investigated how LRP1 regulates mouse retinal angiogenesis.
Approach and results—Depletion of LRP1 in endothelial cells results in increased retinal 
neovascularization in a mouse model of oxygen-induced retinopathy. Specifically, retinas in mice 
lacking endothelial LRP1 have more branching points and angiogenic sprouts at the leading edge 
of the newly formed vasculature. Increased endothelial proliferation as detected by Ki67 staining 
was observed in LRP1 deleted retinal endothelium in response to hypoxia. Using an array of 
biochemical and cell biology approaches, we demonstrate that poly(ADP-ribose) polymerase-1 
(PARP-1) directly interacts with LRP1 in human retinal microvascular endothelial cells (HRECs). 
This interaction between LRP1 and PARP-1 decreases under hypoxic condition. Moreover, LRP1 
knockdown results in increased PARP-1 activity and subsequent phosphorylation of both 
retinoblastoma protein (Rb) and cyclin-dependent kinase 2 (CDK2), which function to promote 
cell cycle progression and angiogenesis.
Conclusions—Together, these data reveal a pivotal role for LRP1 in endothelial cell 
proliferation and retinal neovascularization induced by hypoxia. In addition, we demonstrate for 
the first time the interaction between LRP1 and PARP-1 and the LRP1-dependent regulation of 
PARP-1 signaling pathways. These data bring forth the possibility of novel therapeutic approaches 
for pathological angiogenesis.
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Angiogenesis is the process of new blood vessel growth from existing vascular networks. It 
occurs during embryonic development and throughout adulthood, and is initiated during 
wound healing and in pathological conditions such as retinopathy1. Pathological retinal 
angiogenesis generates physiologically deficient vessels and results in vision-threatening 
exudation and hemorrhage1. Several factors including vascular endothelial growth factor 
(VEGF), angiopoietins, Notch and Wnt have been shown as critical coordinators for retinal 
angiogenesis2–5. However, the exact molecular mechanisms of pathological retinal 
angiogenesis involved in retinopathy of prematurity and diabetic retinopathy remain elusive.
Low density lipoprotein receptor-related protein 1 (LRP1), a multifunctional member of the 
LDL receptor family, is involved in a variety of biological processes such as lipid 
metabolism, endocytosis and signal transduction6–8. Global deletion of the LRP1 gene in 
mice leads to embryonic lethality, demonstrating an essential role for LRP1 in 
development9. More recent work demonstrates that LRP1 deletion in embryo proper results 
in vascular developmental defects10. Tissue specific knockout mouse models show that 
LRP1 regulates cell proliferation and migration in smooth muscle cells, inflammation and 
efferocytosis in macrophages, suggesting that LRP1 plays important roles in 
atherosclerosis11–15. In endothelial cells, we previously demonstrated that LRP1 regulates 
vascular development through its interaction with BMP binding endothelial regulator 
(BMPER) and affecting BMP signaling16. However, whether LRP1 is involved in other 
signaling pathways in endothelial cells and regulates pathological angiogenesis remains 
unknown.
LRP1 is a heterodimer composed of an extracellular 515-kDa α chain (LRP1α) and an 85-
kDa membrane-anchored cytoplasmic β chain (LRP1β), which remain non-covalently 
associated6–8. There are more than forty different ligands for LRP1, such as proteases, 
growth factors, extracellular matrix proteins and lipoproteins. The intracellular domain of 
LRP1β contains multiple serine, threonine and tyrosine residues that can be phosphorylated 
by PKA or Src8. This domain also associates with adaptor proteins via its two NPXY motifs 
to induce signals7. LRP1 mainly behaves as an endocytic receptor for its ligands. For 
example, we recently discovered that LRP1 modulates the endocytosis of BMP signaling 
complex in endothelial cells16. However, some other ligands, including tPA, α2-
macroglobulin (α2M), apoE, matrix metalloproteinase 9, may activate Src/ERK and 
PI3K/Akt/PKCδ signaling pathways in neuronal cells17–21. Moreover, the LPS-induced 
intramembrane proteolysis of LRP1 enables the translocation of its intracellular domain into 
the nucleus and regulates transcriptional events of inflammatory genes22. Taken together, 
LRP1 may activate and integrate diverse downstream signaling pathways in response to 
different stimuli. Interestingly, LRP1 expression can be induced by hypoxia in smooth 
muscle cells and by fluvastatin and simvastatin in human brain microvascular endothelial 
cells23–25. It is plausible that LRP1 may also mediate endothelial cellular responses to 
diverse stimuli or stress through multiple signaling pathways besides of endocytosis. 
However, the LRP1-mediated function of these ligands and modulators in endothelial cells 
remain uncharacterized, warranting further investigation.
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In this study, we investigated whether and how LRP1 deletion in endothelial cells regulates 
pathological angiogenesis by using a mouse model of oxygen-induced retinopathy (OIR). 
Our results demonstrate that LRP1 acts as a negative regulator of retinal angiogenesis under 
hypoxic condition. We also demonstrate that the regulatory role of LRP1 in endothelial cell 
proliferation and angiogenesis fulfills, at least in part, through the interaction of LRP1 with 
PARP-1. This interaction between LRP1 and PARP-1 broadens our understanding about the 
functional roles of LRP1 in endothelial cells and for the first time, reveals a novel regulatory 
role of LRP1 in the PARP-1/CDK2/Rb signaling pathway.
MATERIAL AND METHODS
Materials and Methods are available in the online-only supplement.
RESULTS
LRP1 Deletion in Retinal Endothelium Results in Increased Neovascularization in an 
Oxygen-Induced Retinopathy Mouse Model
We recently discovered that LRP1 regulates vascular development in zebrafish16. To further 
determine the roles of LRP1 in pathological angiogenesis and its underlying mechanisms, 
we decided to utilize an oxygen-induced retinopathy (OIR) mouse model because retinal 
vasculature is a highly organized and easily approachable system to study. To elucidate the 
specific role of LRP1 in endothelial cells, we first crossed LRP1flox/flox (LRP1f/f) mice with 
Tie2Cre+ transgenic mice to generate LRP1f/f;Tie2Cre+/− mice. Tie2 promoter directs 
effective Cre expression, and hence LRP1 deletion, in endothelial cells (Figure 1A) as well 
as hematopoietic cells26. Since retinal vascularization begins at the optic nerve head and 
radiates outwards to cover the most superficial retinal layer during the first week of life 
(between postnatal days P0~P7) in mice27, we examined whether there is a difference during 
the development of this superficial retinal vasculature layer in LRP1f/f;Cre+ mice and 
LRP1f/f;Cre− littermate control mice. However, no obvious gross morphological difference 
was observed, indicating that LRP1 is not essential for retinal vasculature development (data 
not shown). We then investigated the role of LRP1 in pathological angiogenesis by using an 
OIR model28, 29. OIR model starts with postnatal day 7 (P7) mice being placed in a cage 
with constant 75% O2 for five days. This constant hyperoxia induces retinal capillary 
obliteration centrally28, 29. Mice were then placed back into room air to mimic relative 
hypoxia and permit retinal and intravitreous neovascularization. This model pathologically 
mimics the ischemia-induced angiogenesis observed in retinopathy of prematurity and 
proliferative diabetic retinopathy and is relevant in general to ischemic vascular diseases1. 
Using this model, we measured the detailed parameters of blood vessel formation following 
the onset of hypoxia. At 48 hours following the onset of hypoxia (P14), LRP1f/f;Cre+ mice 
displayed 29% more retinal vascularization compared to control littermates, and 22% more 
retinal vascularization at 72 hours (P15) (Figure 1B and 1C). This increase in intraretinal 
neovascularization observed in LRP1f/f;Cre+ mice was accompanied by a denser and more 
complex network of newly formed vessels (Figure 1D) as well as more vascularized area, 
greater number of branching points and more sprouts at the leading edge of the newly 
formed vessels in LRP1f/f;Cre+ mice, compared to their control littermates (Figure 1E–G). 
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These observations demonstrate that LRP1 regulates angiogenic responses of retinal 
endothelial cells to the changes of oxygen tension.
LRP1 Depleted Retinal Endothelium Displays Increased Proliferative Response Without 
Changes in the Interaction of Endothelial Cells with Astrocytes and Pericytes
To determine which cellular processes during retinal neovascularization are affected by 
LRP1 depletion in endothelium, we examined endothelial cell proliferation, the interaction 
of endothelial cells with adjacent astrocytes and pericyte recruitment. First, we examined 
whether endothelial proliferation is affected during the increased angiogenic responses in 
LRP1f/f;Cre+ retinas. We stained retinal cells at 3 days following the onset of hypoxia (P15) 
with Ki67, a specific nuclear marker of cell proliferation. In retinas with LRP1 deletion in 
endothelial cells, we observed a significant increase in Ki67 positive endothelial cell number 
(Figure 2A and 2B), indicating that cell proliferation increased in LRP1 deleted vascular 
endothelium. Next, we investigated the interaction of astrocytes and the LRP1-deleted 
endothelial cells. Immunostaining of retinas following the onset of hypoxia (P14) with iso-
lectin (to stain endothelial cells) and glial fibrillary acidic protein (GFAP, to stain 
astrocytes) revealed that the pattern of retinal astrocytic network in LRP1 depleted retinas 
was not obviously different from the control littermates. Moreover, we observed that 
endothelial cell filopodia at the tip of the growing vascular sprouts were similar between 
LRP1f/f;Cre+ and control retinas (Figure 2C). Specifically, both LRP1 depleted endothelial 
cells and control cells interacted with the astrocytic network similarly, suggesting that the 
communication between astrocytes and endothelial cells is not impaired by LRP1 depletion. 
Furthermore, we examined whether the recruitment of pericytes to the wall of the new 
vessels was abnormal in retinas with LRP1-depleted endothelium. Immunostaining of 
retinas with iso-lectin and NG2 (to stain pericytes) indicated that both LRP1f/f;Cre+ and 
control retinas displayed appropriate coverage of new vessels with pericytes, in a ratio of 
~3:1 (endothelial cell: pericyte), suggesting that the process of pericyte recruitment is not 
disturbed in new vessels lacking LRP1 (Figure 2D). Based on our observation of these 
endothelial cellular processes, this infers that endothelial cell proliferation is regulated by 
LRP1, which may partly contribute to the increased angiogenic activity observed in 
LRP1f/f;Cre+ retinas.
LRP1 Knockdown in Human Retinal Microvascular Endothelial Cells (HRECs) Increases 
Angiogenesis, Endothelial Proliferation and Cell Cycle Progression in Response to 
Hypoxia
Our in vivo data (Figure 1 and 2) indicate that LRP1 depletion in retinal endothelium 
increases endothelial cell proliferation and retinal neovascularization. To identify the precise 
molecular and cellular events involved, we first tested whether LRP1 inhibits angiogenesis 
in cultured primary endothelial cells- Human Retinal Microvascular Endothelial Cells 
(HRECs). LRP1 is endogenously expressed in HRECs, and transfection of its specific 
siRNAs dramatically decreased its protein level (Figure 3A). In a Matrigel tubulogenesis 
assay, mild hypoxia (2% oxygen) predictably increased tube formation compared to 
normoxia. LRP1 knockdown in HRECs results in an additional ~2-fold increase in tube 
formation in mild hypoxia (Figure 3B and 3C). We also observed a similar increase in 
sprouting angiogenesis in response to hypoxia in LRP1 knockdown HRECs (Figure 3D and 
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3E). These in vitro data confirm our observations with LRP1f/f;Cre+ mouse retinas (Figure 
1) and suggest that LRP1 is a negative regulator of angiogenesis. Since retinal angiogenesis 
and endothelial cell proliferation increases in LRP1f/f;Cre+ mice, we investigated the role of 
LRP1 in endothelial cell growth in HRECs. The growth curve of HRECs following LRP1 
knockdown clearly shows that LRP1 knockdown in HRECs increases cell number during 
hypoxia, compared to control siRNA-transfected HRECs (Figure 3F). Lastly, we 
investigated whether LRP1 regulates endothelial proliferative response by affecting cell 
cycle progression. Significantly more HRECs lacking LRP1 progress into S phase from 
G1/G0 stage, compared to control cells in response to hypoxia (Figure 3G and 3H). These 
data establish that LRP1 is a negative regulator of retinal angiogenesis, at least in part 
through cell cycle arrest and the inhibitory effect on endothelial cell proliferation.
LRP1 Interacts with Poly(ADP-Ribose) Polymerase-1 (PARP-1) in HRECs
To elucidate how LRP1 regulates the cell cycle and endothelial cell proliferation, we used 
immunoprecipitation combined with liquid chromatography-mass spectrometry/mass 
spectrometry (LC-MS/MS) as an inductive unbiased method of identifying LRP1-associated 
proteins in HEK 293 cells. We identified Poly(ADP-Ribose) polymerase (PARP-1), a well 
defined stress sensor, as a candidate binding partner of LRP1 in HEK 293 cells (Figure SI, 
Table SI). PARP-1 is a nuclear enzyme that uses NAD+ as a substrate to catalyze the 
covalent attachment of ADP-ribose units on nuclear acceptor proteins or on PARP-1 itself30. 
In response to stress signals, PARP-1 is activated and plays key roles in DNA repair31–33, 
apoptosis34, 35, chromatin modulation and transcription36, 37 and cell cycle regulation38–41. 
Many reports demonstrate that PARP-1 inhibition by genetic deletion or chemical inhibitors 
decreases angiogenesis during melanoma tumor growth, a transplanted lung cancer model or 
other pathological conditions42–45. Due to its role in cell cycle control and angiogenesis, and 
our data suggesting PARP-1 could be a novel interactive protein of LRP1, we tested whether 
PARP-1 regulated the LRP1-mediated effects of endothelial cell cycle progression, 
proliferation and angiogenesis. First, we investigated the subcellular localization of LRP1 
and PARP-1. Confocal imaging of HRECs revealed that PARP-1 and LRP1 (detected by 
LRP1 C-terminal antibody) substantially co-localize in the nucleus and some in the 
cytoplasm of HRECs (Figure 4A). Next, we confirmed their interaction by performing 
immunoprecipitation experiments. Immunoprecipitating for Flag-tagged LRP1 and 
immunoblotting for PARP-1 demonstrated that PARP-1 associates with LRP1 in HEK 293 
cells (Figure 4B). We then performed GST pull down assay to compare the binding of 
PARP-1 with purified GST-tagged LRP1 intracellular C-terminal domain (GST-ICD; a.a. 
4445-4544 of human LRP1) or the truncated intracellular C-terminal domain shortened 
(GST-ICDs; a.a. 4445-4511 of human LRP1). The binding of PARP-1 with GST-ICDs 
decreased significantly, compared to that with GST-ICD (Figure 4C). It indicates that the 
LRP1 C-terminal domain containing last 33 amino acids is required for its interaction with 
PARP-1. The interaction between endogenous LRP1 and PARP-1 was also observed in 
HRECs (Figure 4D–E). Next, we determined how hypoxia affects the subcellular 
localization of LRP1 and PARP-1 and their interaction. Interestingly, when HRECs were 
exposed to hypoxia for 0.5~2 hours, both LRP1 and PARP-1 signals increased in cytoplasm 
but decreased in nucleus, suggesting that they translocate from nucleus to cytoplasm in 
response to hypoxia (Figure SIIIA–C). We also observed that the interaction between LRP1 
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and PARP-1 dramatically decreased in response to hypoxia, compared to normoxia (Figure 
4F), confirmed by our confocal imaging data (Figure SIIID). Together, these data suggest 
that PARP-1 directly associates with LRP1, and their association is dynamically regulated 
by oxygen tension.
LRP1 intracellular domain (~12 kDa) released by intramembrane proteolysis can translocate 
into nucleus and regulate signaling events22, 46. This processing of LRP1 is dependent on 
the presenillin-dependent γ-secretase activity. We asked whether hypoxia regulates the 
processing of this LRP1 intracellular domain. Using subcellular fractionation analysis, we 
observed that under normoxic condition, a fragment at ~12 kDa in the nucleus was detected 
with LRP1 C-terminal antibody (Figure SIV). When DAPT, an inhibitor of presenillin-
dependent γ-secretase activity, was administrated, the ~25 kDa processed form of LRP1 was 
detected in the cytosolic fraction (Figure SIV). This confirms previous reports that the 
intracellular domain of LRP1 (~12 kDa) is processed from the ~25 kDa fragment by the 
presenillin-dependent γ-secretase activity22, 46. However, the protein level of the ~12 kDa 
fragment was not dramatically affected by hypoxia compared to normoxia, suggesting that 
hypoxia does not regulate the presenillin-dependent γ-secretase activity and the processing 
of the ~12 kDa LRP1 fragment. The association of LRP1 and PARP-1 is likely regulated 
through other unknown mechanisms.
PARP-1 is known to be associated with HIF1α47, which is a well-known regulator of 
hypoxia-dependent VEGF induction and angiogenesis48. Is the regulatory role of LRP1 in 
angiogenesis mediated through HIF1α-VEGF pathway? To answer this question, we 
determined the effect of LRP1 knockdown on the induction of HIF1α. As expected, hypoxia 
for 2 and 6 hours induced HIF1α protein in HRECs. Surprisingly, hypoxia-induced HIF1α 
protein decreased dramatically in LRP1 siRNA-transfected HRECs, compared to control 
siRNA-transfected cells (Figure SV). This observation indicates that the angiogenic effect 
resulted from LRP1 knockdown is not likely mediated through HIF1α-VEGF signaling 
pathway.
LRP1 Knockdown Increases the Phosphorylation of CDK2 and Rb by Enhancing PARP-1 
Activity
Progression through the cell cycle is coordinated by the expression and activation of 
multiple components including cyclins, cyclin-dependent kinases (CDKs) and CDK 
inhibitors49. It has been reported that LRP1 depletion in MEFs increases the 
phosphorylation of retinoblastoma (Rb) and cyclin-dependent kinase 2 (CDK2)50, which are 
critical regulators for G1-S transition during cell cycle51, 52. Given that LRP1 knockdown 
increases the number of HRECs entering into S-phase (Figure 3G–H), we tested whether 
LRP1 affected cell cycle progression by modulating Rb and CDK2 activity. LRP1 
knockdown in HRECs significantly increased CDK2 activity, detected by the specific 
phosphorylation at Thr 160 (Figure 5A and 5B). Similarly, LRP1 knockdown increased Rb 
phosphorylation at Ser 807/811 (Figure 5A and 5C), which represents the inactivation of Rb 
that is required for the release of sequestered E2F transcription factors. Given the activation 
of CDK2 and E2F induces the transcription of genes encoding proteins that are required for 
S-phase DNA synthesis51, 52, the enhanced G1-S transition and cell cycle progression due to 
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LRP1 knockdown is likely mediated through the increase in CDK2 and Rb phosphorylation. 
Since PARP-1 is an important cell cycle regulator by interacting with p53 and affecting the 
expression and/or activation of cell cycle modulators including cyclin-dependent kinases 
CDKs and Rb53, 54, we tested whether PARP-1 is a mediator for LRP1 to regulate CDK2 
and Rb activity. First, we determined whether PARP-1 activity is regulated by LRP1 in 
HRECs by performing PAR activity assay. As a stress signal, hypoxia dramatically 
enhanced PARP-1 activity (Figure 5D). Interestingly, LRP1 knockdown further increased 
PAR activity significantly (Figure 5D). Next, we tested whether the inhibition of PARP-1 
enzymatic activity decreases the phosphorylation of CDK2 and Rb, and more importantly, 
‘rescues’ the increase in the phosphorylation of CDK2 and Rb resulted from LRP1 
knockdown. By using an inhibitor of PARP-1 activity- PJ-34 (Figure SVI), we demonstrated 
that the inhibition of PARP-1 activity indeed decreased phosphorylation of CDK2 and Rb at 
both normoxic and hypoxic conditions (Figure 5E–G). Interestingly, PJ-34 inhibited the 
increased phosphorylation of CDK2 and Rb induced by LRP1 knockdown (Figure 5H–J). 
Taken together, we conclude that LRP1 knockdown likely promotes cell cycle progression 
by regulating PARP-1 activity.
In summary, our data indicate that LRP1 is a critical regulator of pathological angiogenesis 
and proliferation in the retinal endothelium. Importantly, we identify that LRP1 acts as a 
direct negative regulator of PARP-1, mediating CDK2 and Rb activity in the endothelium. 
We establish for the first time, this novel mechanism of explaining how LRP1, in part, 
negatively regulates endothelial cell proliferation and neovascularization in the hypoxic 
retina.
DISCUSSION
In this study, we have identified a regulatory role for LRP1 in pathological retinal 
angiogenesis. LRP1f/f;Cre+ mice with LRP1 depleted in endothelial cells display 
significantly more neovascularization response in the retina under hypoxic stress. This 
increase in vessel formation is, at least in part, contributed by the enhanced endothelial 
proliferative responses. We also uncover that PARP-1, a regulator of cell cycle progression, 
is negatively regulated by LRP1 through their dynamic interaction in response to hypoxia. 
These observations establish the notion that LRP1 is a critical regulator of angiogenesis and 
broaden our understanding of the functions that LRP1 exhibits in endothelial cells.
LRP1 is recognized as a multi-functional receptor that is involved in a variety of biological 
processes such as lipid metabolism, endocytosis and signal transduction6–8. In our previous 
study, LRP1 was discovered to be a novel regulator of zebrafish vascular development by 
regulating BMP signaling pathway16. BMP and BMPER are known as critical regulators of 
angiogenesis during development and disease conditions16, 28, 55–59. Our data demonstrate 
that LRP1 depletion in endothelial cells, similar to BMPER haploinsufficiency28, leads to 
increased retinal neovascularization in an OIR mouse model, suggesting that LRP1 might be 
a mediator for BMPER to regulate cell cycle progression and angiogenesis during OIR. 
Since multiple cellular events are involved in retinal angiogenesis, such as proliferation, 
apoptosis and migration, it is likely that LRP1 is also involved in other cellular processes. 
Our data clearly demonstrate that LRP1 negatively regulates proliferative angiogenesis in 
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mouse retina at least in part through regulating cell cycle progression. Interestingly, the 
induction of HIF1α, a well-known angiogenic regulator, is not enhanced by LRP1 
knockdown, suggesting that HIF1α is not likely a mediator of LRP1 depletion-dependent 
angiogenic effect. Further work is needed to elucidate how LRP1 regulates HIF1α-VEGF 
pathway and downstream effects. Although our proposed working model (Figure 5K) is 
oversimplified, it provides an initial framework into the role of LRP1 in endothelial 
function. We propose that, under normoxic conditions, LRP1 is associated with PARP-1 in 
endothelial cells. In response to mild hypoxia, the interaction of LRP1 and PARP-1 
decreases. This dissociation, mimicked by our LRP1f/f;Tie2Cre+/− mice, may result in an 
increase in the PARP-1 enzymatic activity, which in turn leads to the hyperphosphorylation 
of Rb and activation of CDK2, and thereby promoting cell cycle progression. Combined, 
these molecular and cellular changes coordinately contribute to the proliferative and 
angiogenic effects in response to hypoxia.
PARP-1 is the founding and most studied member of the PARP family. It functions as a 
cellular stress sensor, directing cells to specific fates, such as DNA repair, survival, 
proliferation and cell death) based on the type and strength of the stress stimulus. Increasing 
evidence into the role of PARP-1 in the endothelium supports that PARP-1 is involved in 
endothelial dysfunction, atherosclerosis, restenosis and angiogenesis following stress and 
vascular injury30, 37, 54, 60. PARP inhibitors have been developed for therapeutic treatments 
of various cancers since it enhances the death of the malignant cells by interfering with 
cancer cell DNA repair61. Recent findings demonstrating that PARP inhibitors may inhibit 
angiogenesis by decreasing both growth factor expression and cell proliferation make it even 
more attractive cancer drug candidate42–45, 60, 62, 63. Our findings in this report provide 
novel mechanistic insights for PARP’s proliferative and pro-angiogenic roles via LRP1 
regulation. Moreover, it indicates that the PARP-1 inhibitors can not only be applied to 
cancer but also therapeutically against other angiogenesis-related pathologies such as 
proliferative diabetic retinopathy and retinopathy of prematurity.
Poly(ADP-ribosyl)ation (or ‘PARylation’) is a chemical process that is catalyzed by PARP 
whereby PAR polymers are covalent attached on PARP itself and other acceptor proteins, 
including histones, DNA repair proteins, transcription factors, chromatin modulators30. 
Although we observe that LRP1 affects G1-S transition by modulating PARP-1 enzymatic 
activity, the detailed mechanism by which ‘PARylation’ regulates the phosphorylation of 
CDK2 and Rb remains elusive. One possible candidate could be p53 since it regulates 
CDK2 and Rb activity through the regulation of p2153 and the activity of p53 is regulated by 
‘PARylation’ in response to DNA damage64. In addition, PARP-1 is proteolytically cleaved, 
mediating apoptosis. During apoptosis, PARP-1 is cleaved by caspase 3, and possibly other 
proteases, into C-terminal fragment (89 kDa) and N-terminal fragments (24 kDa)65. We 
observed both full length and cleaved PARP-1 at 89 kDa in HRECs in normoxia. However, 
2% oxygen did not increase the amount of cleaved PARP-1 at 89 kDa (Figure 4E), 
indicating that PARP-1 cleavage-mediated apoptosis is not induced by hypoxia at 2% 
oxygen. Instead, HRECs exhibit enhanced cell growth and angiogenic responses (Figure 
3B–E). Therefore, our data indicate that the PARP-1 enzymatic activity, but not the cleavage 
of PARP-1, is required for LRP1-dependent cell cycle regulation. In this study, we have 
determined the role of LRP1 in PARP-1-dependent signaling responses involved in cell 
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cycle progression. In response to various ligands of LRP1, other PARP-1 dependent 
signaling pathways in endothelial cells could also be affected and lead to cellular responses 
such as chromatin structure remodeling and changes in DNA damage response and cell 
viability. The precise roles of LRP1 activity in these pathways remain to be determined. On 
the other hand, how PARP-1 and ‘PARylation’ affect LRP1-mediated cellular processes, 
including lipid metabolism, endocytosis and cellular signaling, becomes another interesting 
focus for the future studies.
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Low density lipoprotein receptor-related protein 1 (LRP1) is a multifunctional member of 
the LDL receptor family, impacting a variety of biological processes such as lipid 
metabolism, endocytosis and signal transduction. However, the role of LRP1 in 
endothelium is almost unknown. Here we studied the functional roles of LRP1 in 
angiogenesis in oxygen-induced retinopathy mouse model. Our data reveal a critical role 
for LRP1 in the regulation of endothelial cell proliferation and neovascularization in the 
hypoxic retina. In addition, these data demonstrate for the first time a dynamic interaction 
of LRP1 and PARP-1 in endothelial cells. These data bring forth the possibility of novel 
therapeutic approaches for pathological angiogenesis such as proliferative diabetic 
retinopathy and retinopathy of prematurity.
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Figure 1. Intraretinal neovascularization increases in retinal endothelium lacking LRP1 during 
hypoxia
A, Loss of LRP1 expression in endothelial cells in LRP1f/f;Cre+ mouse retina. Images are 
sagittal views of mouse retinas at postnatal day P15. Tissue sections were stained with LRP1 
(8G1 Ab, green) and CD31 (an endothelial cell specific marker, red) antibodies. The test for 
the specificity of this 8G1 antibody is shown in Figure SII. INL, inner nuclear layer; IPL, 
inner plexiform layer; SVP, superficial vascular plexus; V, vitreous. B–C, Loss of LRP1 in 
endothelial cells increased intraretinal neovascularization following onset of hypoxia for 48 
hours at P14 and 72 hours at P15. (B) Confocal images of retinal flat mounts from 
LRP1f/f;Cre+/− oxygen-induced retinopathy (OIR) mice were stained with iso-lectin. 
Avascularized (yellow outline) areas are shown as a percentage of the total area of the 
retinal superficial vasculature layer (C). *, P<0.05 via two-way ANOVA analysis followed 
by Bonferroni multiple comparison test, n≥4. D–G, Analysis of angiogenic parameters for 
the retinal neovascularization. D, An increase in neovascularization is observed at the 
leading edge of LRP1f/f;Cre+ retinas, compared to LRP1f/f;Cre− littermates. Confocal 
images of retinal flat mounts stained with iso-lectin from P15 LRP1f/f;Cre+/− oxygen-
induced retinopathy mice were used for analysis. Vascularized area (E), branching pints (F) 
and vessel sprout number (G) were quantified within leading edge of neovascularization 
area. *, P<0.05 via unpaired Student’s t-test, n=4 for LRP1f/f;Cre− and n=3 for LRP1f/f;Cre+ 
mice.
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Figure 2. LRP1 deletion in retinal endothelium displays increased proliferation without changes 
in the interaction of endothelial cells with astrocytes and pericytes
A–B, Endothelial cell proliferation increases in LRP1f/f;Cre+ mice. (A) Retinal sagittal 
sections from P15 (72 hours of hypoxia) LRP1f/f;Cre+/− mice were stained with Ki67 (cell 
proliferation marker, green), CD31 (endothelial cell marker, red) and DAPI (blue). The 
percentage of Ki67 positive endothelial cells were counted and presented in B. Arrows, Ki67 
positive endothelial cells. *, P<0.05 via unpaired Student’s t-test, n=6 for LRP1f/f;Cre− and 
n=5 for LRP1f/f;Cre+ mice. C–D, Normal astrocyte-endothelial filopodia interactions and 
pericyte recruitment are observed in both LRP1f/f;Cre+ and LRP1f/f;Cre− mouse retinas. 
Flat-mounted whole retinas from LRP1f/f;Cre+/− mice that were subjected to OIR for 48 
hours were stained with iso-lectin (red), glial fibrillary acidic protein (GFAP; green in C) or 
NG2 (green in D). Arrows, endothelial filopodia.
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Figure 3. LRP1 knockdown in HRECs promotes angiogenesis, endothelial proliferation and cell 
cycle progression
A, LRP1 protein level decreases in HRECs that were transfected with LRP1 siRNA, 
compared to control siRNA. Lysates of LRP1-knockdown or control HRECs treated were 
analyzed by Western blotting to detect LRP1 β chain at 85 kDa. B–C, LRP1 knockdown in 
HRECs increases tube formation. HRECs were incubated in normoxia (21% O2) or hypoxia 
(2% O2) condition for 24 hours on Matrigel coated plates. Phase contrast images were used 
for quantitative measurements of tube numbers per sample and shown in B. *, P<0.05 
compared to the same HRECs at normoxia condition, #, P<0.05 compared to the control 
siRNA-treated HRECs at hypoxia condition, n=3. Analysis was two-way ANOVA followed 
by Bonferroni multiple comparison test. D–E, LRP1 knockdown in HRECs increases 
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sprouting angiogenesis. Spheroid angiogenesis assays were performed with HRECs that 
were transfected with LRP1 or control siRNAs. Hypoxia (2% O2) was used to induce sprout 
formation. Images of HRECs spheroids demonstrate the formation of sprouts following 72 
hours of hypoxia (2% O2) incubation. The number of sprouts per spheroid were counted and 
quantified in E. *, P<0.05 via unpaired Student’s t-test compared to control cells, n=6. F, 
LRP1 knockdown in HRECs increases hypoxia-induced cell growth. Cell numbers were 
counted daily in HRECs that were transfected with LRP1 or control siRNAs, and 
subsequently cultured in normoxia or hypoxia (2% O2) for 4 days. *, P<0.05, compared to 
same HRECs at day 0. #, P<0.05, compared to control siRNA-transfected HRECs that were 
incubated at hypoxia condition. n= 4. Analysis was two-way ANOVA followed by 
Bonferroni multiple comparison test. G–H, LRP1 knockdown increases cell cycle 
progression to S phase from G1/G0 stage. HRECs were transfected with LRP1 or control 
siRNA. Two days later, cells were incubated under normoxia (N, 21% O2) or hypoxia (H, 
2% O2) for 24 hours. Cells were then stained with propidium iodide and analyzed by flow 
cytometry. The representative flow cytometry images are shown in G, and the percentages 
of cells at different cell cycle stages were quantified and present in H. *, P<0.05, compared 
to same cells under normoxia. #, P<0.05, compared to control siRNA-transfected HRECs 
under hypoxia. n=3. Analysis was two-way ANOVA followed Fisher’s LSD multiple 
comparison test.
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Figure 4. LRP1 interacts with PARP-1 in HRECs
A, HRECs were fixed for staining with anti-LRP1 (LRP1-CTD Ab, green) and PARP-1 
antibodies (red) and DAPI (blue), and imaged with confocal microscopy. The test for the 
specificity of this LRP1-CTD antibody is shown in Figure SII. B, Lysates of HEK 293 cells 
with stable exogenously expressing Flag-tagged LRP1 β chain (Flag-LRP1) were 
immunoprecipitated with an anti-Flag resin and blotted with an anti-PARP-1 antibody. C, 
GST pull down assays were performed with HREC lysates. GST-fusion proteins were 
generated for GST-tagged LRP1 intracellular C-terminal domain (GST-ICD; a.a. 4445-4544 
of human LRP1) and a truncated LRP1 intracellular C-terminal domain shortened (GST-
ICDs; a.a. 4445-4511 of human LRP1) constructs, or GST as a negative control. Western 
blotting analysis was performed with anti-PARP-1 antibody. D, Lysates of HRECs were 
immunoprecipitated with anti-LRP1 antibody or control IgG and analyzed by Western 
blotting with an anti-PARP-1 antibody. E, Lysates of HRECs were immunoprecipitated with 
anti-PARP-1 antibody or control IgG and analyzed by Western blotting with an anti-LRP1 
(LRP1-CTD) antibody. F, Hypoxia decreases the interaction of LRP1 and PARP-1 in 
HRECs. Lysates of HRECs following either normoxia (21% O2) or hypoxia (2% O2) 
exposure for 2 hours were immunoprecipitated with anti-LRP1 antibody or control IgG and 
analyzed by Western blotting with an anti-PARP-1 antibody. The associated PARP-1 full-
length protein (PARP-1-FL, 116 kDa) and its cleaved form at 89 kDa (cleaved PARP-1) are 
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quantified as percentages of total PARP-1 protein amount. *, P<0.05 via unpaired Student’s 
t-test, n=4.
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Figure 5. LRP1 knockdown increases PARP-1 activity-dependent phosphorylation of Rb and 
CDK2 in HRECs
A–C, LRP1 knockdown increases CDK2 and retinoblastoma (Rb) phosphorylation. HRECs 
were transfected with LRP1 or control siRNA. Two days later, cells were incubated under 
normoxia (21% O2) or hypoxia (2% O2) for 2 hours. Cell lysates were immunoblotted with 
indicated antibodies. The ratios of the phosphorylated CDK2 and Rb to their total respective 
protein amounts were quantified by Image J (B and C). D, PARP-1 activity increased in 
LRP1 knockdown HRECs in response to hypoxia at 2% O2. ELISA enzymatic assay for 
PARP-1 was performed with PAR as a substrate of PARP-1 coated in the plate. Quantitative 
data were presented as a ratio of relative light unit to protein amount in cell lysates. E–G, 
PARP-1 inhibition decreases CDK2 and retinoblastoma (Rb) phosphorylation. HRECs were 
incubated with PARP-1 inhibitor PJ-34 at 3 μM and under normoxia (21% O2) or hypoxia 
Mao et al. Page 21













(2% O2) for 2 hours. Cell lysates were immunoblotted with indicated antibodies. The ratios 
of the phosphorylated CDK2 and Rb to their total respective protein amounts were 
quantified by Image J (F and G). H–J, PJ-34 blocks the increases in CDK2 and 
retinoblastoma (Rb) phosphorylation following LRP1 knockdown. HRECs were transfected 
with LRP1 or control siRNA. Two days later, cells were treated with PARP-1 inhibitor 
PJ-34 at 3 μM and incubated under normoxia (21% O2) or hypoxia (2% O2) for 2 hours. Cell 
lysates were immunoblotted with indicated antibodies. The ratios of the phosphorylated 
CDK2 and Rb to their total respective protein amounts were quantified by Image J (I and J). 
K, Schematic illustration to shown how LRP1 regulates cell cycle progression, endothelial 
proliferation and retinal angiogenesis induced by hypoxia. *, P<0.05, compared to same 
cells under normoxia. #, P<0.05, compared to control HRECs exposed to same oxygen 
level. **, P<0.05, compared to LRP1 siRNA-transfected cells without treatment of PJ-34 
inhibitors. n=3. All data were analyzed with two-way ANOVA analysis followed by the 
Fisher’s LSD or Turkey multiple comparison test.
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